Corina Intrauterine Drug-Eluting System ("Corina"), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. ("YPR"), has received approval in China (G.X.Z.Z. 20243181461) for use in patients with...

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, announces new Customer Engagement solutions leveraging both Trinity’s deep commercial insight and...

ImmPACT Bio USA Inc.a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational benefits to patients, announced the...

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi® (seladelpar) for the treatment of primary biliary cholangitis (PBC) in...

Vapourtec has launched the Peptide-ExplorerLT aimed at chemists looking to explore and optimize linear peptide synthesis.

XiFin, Inc., a leading provider of innovative healthcare information technologies and services that deliver artificial intelligence (AI)-enabled operational efficiency, interoperability, and...

AptarGroup, Inc. a global leader in drug and consumer product dosing, dispensing and protection technologies, announced that its Unidose Liquid System (Unidose) is the delivery system approved with...

Bavarian Nordic A/S announced a new order from HERA (the European Health Emergency Preparedness and Response Authority) for the Company’s MVA-BN® vaccine, the only FDA and EMA-approved mpox vaccine.

Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy aging, is excited to announce the development of a novel, science-backed skincare...

Spencer Trask & Co. the advanced technology development firm, announced today the launch of Signal12 Inc. (Signal12), a clinical-stage dry eye company. Signal12 is revolutionizing treatments for Dry...

Persist AI and Nivagen have announced a collaboration to co-develop a next-generation manufacturing process for long-acting injectable (LAI) drugs, using Persist's AI-based formulation technology...

Biosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical...